The unifying theme of the Tumor Signaling & Angiogenesis program is to build translational clinical trials based on innovative and novel research projects that focus on signaling cascades leading to uncontrolled cell growth and resistance to apoptosis.
The program goals are to identify dysregulated molecular signaling pathways that can be used as cancer-specific targets. Collectively the members of this program work cooperatively to study a variety of kinase targets involved in cancer cell proliferation and progression.
Targets identified in this program can be exploited to develop innovative approaches to cancer prevention and therapy that can be translated into clinical trials. The research into cancer cell signaling incorporates animal models in breast and colon cancer, as well as the pediatric cancer neuroblastoma, to study how specific signaling pathways are involved in the progression of cancer.
Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer are at increased risk of dying early from their disease, researchers report.
Learn how a researcher at the Georgia Cancer Center is working to eliminate Georgia's breast cancer disparities.
Georgia Cancer Center researcher tackles clinical trial hesitancy in the Black community in the southeast.
MCG and Georgia Cancer Center scientists have early evidence that the peptide EnnA, isolated from a fungus living symbiotically with a flowering plant known for its penchant of trapping flies, could be a powerful opponent of aggressive triple negative breast cancer.
